The EU Commission opens formal investigation into a pharmaceutical company pricing practices (Aspen Pharma)

Antitrust: Commission opens formal investigation into Aspen Pharma's pricing practices for cancer medicines* The European Commission has opened a formal investigation into concerns that Aspen Pharma has engaged in excessive pricing concerning five life-saving cancer medicines. The Commission will investigate whether Aspen has abused a dominant market position in breach of EU antitrust rules. Commissioner Margrethe Vestager, in charge of competition policy, said: "When we get sick, we may depend on specific drugs to save or prolong our lives. Companies should be rewarded for producing these pharmaceuticals to ensure that they keep making them into the future. But when the price of a drug suddenly goes up by several hundred

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

Quotation

European Commission, The EU Commission opens formal investigation into a pharmaceutical company pricing practices (Aspen Pharma), 15 May 2017, e-Competitions Bulletin May 2017, Art. N° 84199

Visites 110

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues